New adaptive radiation aims to hit cancer harder, spare healthy tissue
NCT ID NCT07324798
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new way to deliver radiation for prostate and bladder cancers. The approach uses an MRI-guided machine to adapt the radiation dose in real time, giving a higher boost to the tumor while sparing nearby organs. Researchers want to see if this reduces side effects and keeps cancer under control. The trial will enroll 60 adults who have not had radiation in the same area before.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adaptive radiation therapy (MR-guided boost)
- What this could lead to
- If successful, this approach could offer a more precise radiation treatment that reduces side effects while controlling cancer effectively.
- What could go wrong
- This is an early-stage study with only 60 participants, so results may not apply broadly. The technique is complex and may not improve outcomes over standard radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, National Cancer Center, CAMS & PUMC
RECRUITINGBeijing, Beijing Municipality, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer spot prostate cancer return better than the standard scan?
- Can a Bag-Like device pull bladder tumors out whole?
- Can Pre-Surgery chemotherapy outsmart aggressive bladder cancer?
- Bladder cancer: a new combo aims to avoid radical surgery
- Could a simple urine test spare bladder cancer patients from chemotherapy?
- Can a new drug rally the immune system against Hard-to-Treat cancers?